16 Spam-Free Article(s) Found
Sort:
Like
Filter:
All
Article Searches
Moderna (MRNA) Soars on Upbeat Data From Cancer Therapy Study https://www.zacks.com/stock/news/2198897/moderna-mrna-soars-on-upbeat-data-from-cancer-therapy-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2198897 Dec 15, 2023 - Three-year follow up data from a mid-stage study shows that treatment with Moderna (MRNA)/Merck's cancer combination therapy reduces recurrence/death risk in certain melanoma patients by half.
Merck's (MRK) Chronic Cough Drug Gets Another CRL From FDA https://www.zacks.com/stock/news/2201156/merck-s-mrk-chronic-cough-drug-gets-another-crl-from-fda?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2201156 Dec 21, 2023 - Per the FDA, the data submitted by Merck (MRK) for its chronic cough drug did not provide sufficient evidence to prove its clinical benefit in patients.
Down -14.35% in 4 Weeks, Here's Why Galapagos NV (GLPG) Looks Ripe for a Turnaround https://www.zacks.com/stock/news/2242089/down-14-35-in-4-weeks-here-s-why-galapagos-nv-glpg-looks-ripe-for-a-turnaround?cid=CS-ZC-FT-tale_of_the_tape|rsi-2242089 Mar 18, 2024 - Galapagos NV (GLPG) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Bayer's (BAYRY) Elinzanetant Meets Goals in Third Phase III Study https://www.zacks.com/stock/news/2243694/bayer-s-bayry-elinzanetant-meets-goals-in-third-phase-iii-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2243694 Mar 20, 2024 - Bayer's (BAYRY) pipeline candidate, elinzanetant, achieves primary and secondary goals in late-stage OASIS 3 study supporting submissions for marketing authorization.
Bristol Myers (BMY) Wins EC Nod for Reblozyl Label Expansion https://www.zacks.com/stock/news/2249839/bristol-myers-bmy-wins-ec-nod-for-reblozyl-label-expansion?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2249839 Apr 03, 2024 - Bristol Myers (BMY) receives European Commission's approval for a label expansion of Reblozyl (luspatercept) for another indication.
After Plunging -7.94% in 4 Weeks, Here's Why the Trend Might Reverse for Galapagos (GLPG) https://www.zacks.com/stock/news/2249692/after-plunging-7-94-in-4-weeks-here-s-why-the-trend-might-reverse-for-galapagos-glpg?cid=CS-ZC-FT-tale_of_the_tape|rsi-2249692 Apr 03, 2024 - The heavy selling pressure might have exhausted for Galapagos (GLPG) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Fate Therapeutics (FATE) Surges 86.4% YTD on Pipeline Progress https://www.zacks.com/stock/news/2251537/fate-therapeutics-fate-surges-86-4-ytd-on-pipeline-progress?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2251537 Apr 05, 2024 - Fate Therapeutics (FATE) gains 86.4% on encouraging pipeline progress of its cellular immunotherapies for cancer.
New Strong Buy Stocks for December 13th https://www.zacks.com/commentary/2195934/new-strong-buy-stocks-for-december-13th?cid=CS-ZC-FT-zacks_1_rank_additions-2195934 Dec 13, 2023 - TZOO, GLPG, BBVA, TW and STNE have been added to the Zacks Rank #1 (Strong Buy) List on December 13, 2023.
Best Momentum Stocks to Buy for December 13th https://www.zacks.com/commentary/2197102/best-momentum-stocks-to-buy-for-december-13th?cid=CS-ZC-FT-zacks_1_rank_additions|momentum_additions-2197102 Dec 13, 2023 - GLPG, BBVA and TW made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on December 13, 2023.
Merck (MRK) Gets EU Nod for Expanded Use in Gastric Cancer https://www.zacks.com/stock/news/2200047/merck-mrk-gets-eu-nod-for-expanded-use-in-gastric-cancer?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2200047 Dec 19, 2023 - Following these approvals, Merck's (MRK) Keytruda is approved for seven gastrointestinal cancers in the European Union. Overall, the drug is approved for 26 indications in the region.

Pages: 12

Page 1